scholarly journals A comparative study of effects of omega-3 fatty acids, alpha lipoic acid and vitamin E in type 2 diabetes mellitus

2013 ◽  
Vol 3 (3) ◽  
pp. 442 ◽  
Author(s):  
P Nahar ◽  
S Shah ◽  
M Kshirsagar ◽  
B Ghongane ◽  
A Udupa
2009 ◽  
Vol 90 (3) ◽  
pp. 613-620 ◽  
Author(s):  
Manas Kaushik ◽  
Dariush Mozaffarian ◽  
Donna Spiegelman ◽  
JoAnn E Manson ◽  
Walter C Willett ◽  
...  

Folia Medica ◽  
2013 ◽  
Vol 55 (1) ◽  
pp. 55-63 ◽  
Author(s):  
Mitko D. Mitkov ◽  
Ivanka Y. Aleksandrova ◽  
Maria M. Orbetzova

Abstract Erectile dysfunction (ED) is the inability to develop and/or maintain an erection that is sufficient for satisfactory sexual intercourse. The prevalence of erectile dysfunction in diabetic men is 28-75%, this percentage rising with patient’s age and duration of diabetes. The aim of the present study was to investigate erectile dysfunction and quality of life in patients with type 2 diabetes mellitus (T2DM) after treating them with transdermal testosterone or with alpha-lipoic acid. Materials and methods: The effect of a 12-week treatment with transdermal testosterone or alpha-lipoic acid on the erectile function and quality of life of 45 men with ED and T2DM was studied in a randomized, prospective, open clinical, comparative study. The parameters we measured in the patients were body weight and body mass index (BMI); the albumin, lipids, HbA1C, testosterone (T), sex hormone-binding globulin (SHBG), follicle stimulating hormone (FSH), luteinizing hormone (LH) and microalbuminuria levels; the International Index of Erectile Function (IIEF) and Health related quality of life (SF-36) questionnaires were completed to evaluate ED and quality of life before and after 12 weeks of treatment with alpha-lipoic acid (600 mg, parenterally, for 7 days, followed by 600 mg received per os) or with transdermal testosterone in a dose of 50 mg daily. Results: Testosterone treatment decreased BMI significantly (p < 0.01), increased testosterone concentrations (p < 0.01) and raised the SHBG levels (p < 0.05), improved the glycemic control and lipid profile (total cholesterol, p < 0.05; HDL cholesterol, p < 0.05; triglycerides, p < 0.05). The patients treated with alpha-lipoic acid had their BMI (p < 0.01), HbA1C (p < 0.01), total cholesterol (p < 0.01), HDL-cholesterol (p < 0.01) and triglycerides (p < 0.01) significantly reduced. The indicators for ED in both groups were also statistically significantly improved. There was improvement for all patients’ self-assessment score for “physical functioning” (p = 0.001), for “role limitations due to physical health” (p < 0.001) and for “general health perception” (p = 0.021). Conclusions: Transdermal testosterone and alpha-lipoic acid have a tangible beneficial effect on erectile dysfunction and on metabolic disorders in T2DM patients and can be used to treat such patients.


Sign in / Sign up

Export Citation Format

Share Document